Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 10/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610808 | 0.87 | HCAR3 (0.52) | HCAR3HCAR2NNMT | |
| SCHEMBL186474 | 0.83 | HCAR3 (1.00) | HCAR3HCAR2FYN | |
| SCHEMBL23133523 | 0.81 | HCAR3 (0.65) | HCAR3HPGDSMN1; SMN2HCAR2ALDH1A1 | |
| SCHEMBL15934991 | 0.79 | HCAR3 (0.66) | HCAR3HCAR2NNMT | |
| SCHEMBL856048 | 0.78 | VNN1 (0.50) | HCAR3HPGDSMN1; SMN2HCAR2ALDH1A1 | |
| SCHEMBL23682992 | 0.78 | VNN1 (0.49) | HCAR3NNMT | |
| SCHEMBL3500410 | 0.74 | HCAR3 (0.63) | HCAR3SMN1; SMN2ALDH1A1 | |
| SCHEMBL3500691 | 0.74 | HCAR3 (0.63) | HCAR3SMN1; SMN2ALDH1A1 | |
| SCHEMBL7945395 | 0.74 | HDAC3 (0.53) | ALDH1A1FYN | |
| SCHEMBL22047713 | 0.74 | HCAR3 (1.00) | HCAR3HCAR2FYNEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | HCAR3 123/4885HPGD 3019/4885SMN1; SMN2 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.